Mobile App

Google Play Apple Store
Podcast from EHA 2024 - Advancements in Myelofibrosis From Pathophysiology to Personalized Treatment Strategies
AMA/ABS/ANCC - Podcast
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.
Review the activity to claim AMA/ABS/ANCC credit after completion of the brief Post-Test/Evaluation(s).




 
John Mascarenhas, MD John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of the Center of Excellence
for Blood Cancers and Myeloid Disorders
New York, New York
Yes

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2024 EHA Annual Congress.
20
Supported by an independent educational grant from CTI Biopharma Corp., a Sobi company

Launch Date: June 17, 2024
Release Date: June 17, 2024
Expiration Date: May 31, 2025

Mini Module
7754
EHAConf_CC_PediatricMyelofibrosis_Podcast(1730x162).png
True
Hematology-Oncology

CookieConsent

Change Settings